AU2017220738B2 - Carboxamide derivatives useful as RSK inhibitors - Google Patents

Carboxamide derivatives useful as RSK inhibitors Download PDF

Info

Publication number
AU2017220738B2
AU2017220738B2 AU2017220738A AU2017220738A AU2017220738B2 AU 2017220738 B2 AU2017220738 B2 AU 2017220738B2 AU 2017220738 A AU2017220738 A AU 2017220738A AU 2017220738 A AU2017220738 A AU 2017220738A AU 2017220738 B2 AU2017220738 B2 AU 2017220738B2
Authority
AU
Australia
Prior art keywords
compound
optionally substituted
formula
alkyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017220738A
Other languages
English (en)
Other versions
AU2017220738A1 (en
Inventor
Subhash Annedi
Timothy S. Daynard
Sandra E. Dunn
My-my HUYNH
Aarthi JAYANTHAN
Jaipal Reddy Nagireddy
John H. Van Drie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phoenix Molecular Designs Ltd
Original Assignee
Phoenix Molecular Designs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenix Molecular Designs Ltd filed Critical Phoenix Molecular Designs Ltd
Publication of AU2017220738A1 publication Critical patent/AU2017220738A1/en
Application granted granted Critical
Publication of AU2017220738B2 publication Critical patent/AU2017220738B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2017220738A 2016-02-19 2017-02-17 Carboxamide derivatives useful as RSK inhibitors Active AU2017220738B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662297522P 2016-02-19 2016-02-19
US62/297,522 2016-02-19
PCT/IB2017/000237 WO2017141116A1 (en) 2016-02-19 2017-02-17 Carboxamide derivatives useful as rsk inhibitors

Publications (2)

Publication Number Publication Date
AU2017220738A1 AU2017220738A1 (en) 2018-08-30
AU2017220738B2 true AU2017220738B2 (en) 2022-02-24

Family

ID=59625645

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017220738A Active AU2017220738B2 (en) 2016-02-19 2017-02-17 Carboxamide derivatives useful as RSK inhibitors

Country Status (14)

Country Link
US (4) US9771366B2 (enExample)
EP (2) EP3416964B1 (enExample)
JP (2) JP6912486B2 (enExample)
KR (1) KR102746242B1 (enExample)
CN (2) CN109071542B (enExample)
AU (1) AU2017220738B2 (enExample)
CO (1) CO2018008846A2 (enExample)
DK (1) DK3416964T3 (enExample)
ES (1) ES2858753T3 (enExample)
IL (1) IL261170B (enExample)
MX (1) MX376974B (enExample)
PL (1) PL3416964T3 (enExample)
PT (1) PT3416964T (enExample)
WO (1) WO2017141116A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
WO2016150884A1 (en) 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US11918687B2 (en) 2016-01-15 2024-03-05 Orbsen Therapeutics Limited SDC-2 exosome compositions and methods of isolation and use
WO2017141116A1 (en) * 2016-02-19 2017-08-24 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
AU2018300272B2 (en) 2017-07-14 2024-09-19 Orbsen Therapeutics Limited CD39 stromal stem cells methods of isolation and use
BR112020024019A2 (pt) 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
CN109847063B (zh) * 2018-12-26 2023-02-28 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） Rsk信号通路抑制剂在抑制沙眼衣原体感染中的应用
CN109438403A (zh) * 2018-12-28 2019-03-08 凯瑞斯德生化(苏州)有限公司 一种5-氨基苯并呋喃-2-甲酸乙酯的制备方法
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
TW202307005A (zh) * 2021-05-28 2023-02-16 美商邊際分析公司 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法
SMT202500447T1 (it) 2021-11-02 2026-01-12 Flare Therapeutics Inc Agonisti inversi di pparg e loro usi
US20260193283A1 (en) * 2022-06-07 2026-07-09 Kinoteck Therapeutics Co., Ltd. Carboxamide derivative having rsk inhibitory effect, pharmaceutical composition comprising same, and use thereof
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020875A1 (en) * 1996-11-15 1998-05-22 Eli Lilly And Company 5-ht1f agonists
WO2005005414A2 (en) * 2003-07-08 2005-01-20 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2008156573A1 (en) * 2007-06-12 2008-12-24 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
WO2011071725A1 (en) * 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
JP2001501946A (ja) 1996-10-08 2001-02-13 イーライ・リリー・アンド・カンパニー 新規セロトニン５―ｈｔ▲下１ｆ▼アゴニスト
AU741482B2 (en) 1997-05-07 2001-11-29 Allergan Pharmaceuticals International Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
EP1495016A2 (en) * 2002-04-09 2005-01-12 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
CA2881078C (en) * 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
NZ583689A (en) 2007-09-14 2012-04-27 Univ Michigan F1f0-atpase inhibitors and related methods
GB0718870D0 (en) 2007-09-27 2007-11-07 Univ Dundee Modulation of RSK
US9150577B2 (en) 2009-12-07 2015-10-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
WO2013181742A1 (en) 2012-06-04 2013-12-12 Phoenix Molecular Diagnostics Ltd. Methods of inhibiting rsk for treatment of breast cancer
EP2943485B1 (en) * 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
CN103724251B (zh) * 2014-01-18 2015-07-22 福州大学 一种靶向stat3的小分子化合物及其制备方法和应用
CA2944610C (en) 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
WO2017141116A1 (en) 2016-02-19 2017-08-24 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020875A1 (en) * 1996-11-15 1998-05-22 Eli Lilly And Company 5-ht1f agonists
WO2005005414A2 (en) * 2003-07-08 2005-01-20 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2008156573A1 (en) * 2007-06-12 2008-12-24 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
WO2011071725A1 (en) * 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1789841-92-4; STN Entry Date 28 Jun 2015; 3-Pyridinecarboxamide, N-[2-(trifluoromethyl)-1H-indol-5-yl]- *
CAS Registry Number 1790418-43-7; STN Entry Date 28 Jun 2015; Benzamide, 3,4-dichloro-N-[2-(trifluoromethyl)-1H-indol-5-yl]- *
CAS Registry Number 1790836-52-0; STN Entry Date 29 Jun 2015; Urea, N-[4-(1,1-dimethylethyl)phenyl]-N'-[2-(trifluoromethyl)-1H-indol-5-yl]- *
R. M. FRYER ET AL: , JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 340, no. 3, March 2012 (2012-03-01), pages 492 - 500 *
Rico-Bautista et al. BMC Biology 2010, 8:153 *

Also Published As

Publication number Publication date
WO2017141116A8 (en) 2017-11-09
IL261170A (en) 2018-10-31
EP3848373A1 (en) 2021-07-14
EP3416964B1 (en) 2020-12-16
CN109071542B (zh) 2021-07-20
JP7289876B2 (ja) 2023-06-12
MX376974B (es) 2025-03-07
JP2021176857A (ja) 2021-11-11
CN109071542A (zh) 2018-12-21
DK3416964T3 (da) 2021-02-22
JP6912486B2 (ja) 2021-08-04
IL261170B (en) 2021-12-01
CA3014395A1 (en) 2017-08-24
US20170240549A1 (en) 2017-08-24
US9771366B2 (en) 2017-09-26
WO2017141116A1 (en) 2017-08-24
US10081632B2 (en) 2018-09-25
ES2858753T3 (es) 2021-09-30
EP3416964A4 (en) 2019-09-18
CN113620950A (zh) 2021-11-09
US20190134029A1 (en) 2019-05-09
AU2017220738A1 (en) 2018-08-30
CO2018008846A2 (es) 2018-11-13
US20170327501A1 (en) 2017-11-16
US10758530B2 (en) 2020-09-01
PL3416964T3 (pl) 2021-10-18
BR112018016968A2 (pt) 2019-01-08
EP3416964A1 (en) 2018-12-26
JP2019505541A (ja) 2019-02-28
KR20180129783A (ko) 2018-12-05
PT3416964T (pt) 2021-03-09
KR102746242B1 (ko) 2024-12-23
MX2018010028A (es) 2019-01-21
US20210186961A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
JP7289876B2 (ja) Ｒｓｋ阻害剤として有用なカルボキサミド誘導体
ES2930312T3 (es) Uso de un derivado de pteridinona como inhibidor del EGFR
ES2829914T3 (es) Tratamiento de enfermedades malignas de células B mediante una combinación de inhibidor de JAK y PI3K
AU2006239632B2 (en) Novel AZA- heterocycles serving as kinase inhibitors
US20210032251A1 (en) Heterobicyclic amides as inhibitors of cd38
ES2699948T3 (es) Compuestos de heteroarilo sustituido y métodos de uso
US11667631B2 (en) FGFR4 inhibitor, preparation method therefor, and applications thereof
ES2535607T3 (es) Derivados de 7-([1,2,3]triazol-4-il)-pirrolo[2,3-B]pirazina
ES2528447T3 (es) Derivados de pirazoloquinolina como inhibidores de ADN-PK
BR112015028501B1 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
ES2543563T3 (es) Derivados de 5-([1,2,3]triazol-4-il)-7H-pirrolo[2,3-D]pirimidina
EA019534B1 (ru) ПРОИЗВОДНЫЕ 3-(3-ПИРИМИДИН-2-ИЛБЕНЗИЛ)-1,2,4-ТРИАЗОЛО[4,3-b]ПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Met КИНАЗЫ
US20240166617A1 (en) Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
CA3231988A1 (en) Azaindazole macrocycle compound and use thereof
CN108191837A (zh) PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
CN121758446A (zh) 咪唑酮类化合物及其制备方法和应用
JP6847942B2 (ja) 二環式複素環式誘導体
ES2656096T3 (es) Nuevos derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
CA3014395C (en) Carboxamide derivatives useful as rsk inhibitors
WO2022032284A1 (en) Macrocyclic compounds
BR112018016968B1 (pt) Composto,composição farmacêutica e uso do mesmo para preparo de um medicamento para tratamento de câncer
HK1260540B (en) Carboxamide derivatives useful as rsk inhibitors
HK1260540A1 (en) Carboxamide derivatives useful as rsk inhibitors
WO2016153394A1 (ru) Применение новых химических соединений (варианты) в качестве ингибиторов nuak1 киназы для лечения онкологических заболеваний
HK1228887A1 (en) Thienopyrimidines as mknk1 and mknk2 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)